Moon Surgical
PARIS, FRANCE and SAN FRANCISCO, CA / ACCESSWIRE / April 12, 2023 / Moon Surgical, a French-American pioneer in collaborative robotics, announced today that its Maestro System is now CE Marked under the Medical Device Regulation (EU) 2017/745.
"This new milestone is a testament to our team's hard work and dedication, and attests to the effective ramp-up of our manufacturing and quality operations," said Anne Osdoit, CEO of Moon Surgical, and a Partner in Sofinnova Partners' medtech accelerator, MD Start. "With the Maestro System, we aim to empower surgeons to perform laparoscopy with greater ease, precision, and control, improving patient outcomes and enhancing the overall surgical experience."
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Thus far, fifty patients in Europe have benefited from a Maestro-assisted surgery in a clinical trial led by Pr. Guy-Bernard Cadière in Brussels, Belgium.
Globally, over 18 million patients undergo soft tissue procedures annually without the advantages of robotic surgical platforms. With the Maestro System, Moon Surgical is developing a new category of surgery that enhances traditional laparoscopy. Its state-of-the-art surgical assistance platform is specifically designed to augment the precision and control of laparoscopic surgery, supporting high-volume surgeons performing procedures such as cholecystectomy and hernia repairs and more complex multi-quadrant procedures.
Moon Surgical was founded by Professor Brice Gayet, a world-renowned laparoscopic surgeon, and incubated by Sofinnova Partners MD Start in 2020; it has moved swiftly since. The company raised $31m in May 2022, and, shortly after, announced the completion of a First-in-Human study and FDA clearance for an initial version of its Maestro system, in December of 2022.
About Moon Surgical
Moon Surgical, based in Paris, France, and San Francisco, California, believes the future of the operating room lies in the hands of the empowered surgeon.
By equipping surgeons with complete control, renewed confidence, and adaptable technology to any situation, Moon Surgical strives to improve efficiency in operating rooms and provide better surgical care for patients. The minimalistic, co-manipulation Maestro System uses tomorrow's technology to deliver these vital skills to surgeons, today.
Contact
Investors and Media: info@moonsurgical.com
Moon Surgical® and Maestro® are registered trademarks of Moon Surgical, SAS
SOURCE: Moon Surgical
View source version on accesswire.com:
https://www.accesswire.com/748637/Maestro-Surgical-Robotics-System-by-Moon-Surgical-Now-CE-Marked
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Loar Announces Launch of Secondary Public Offering13.5.2025 16:26:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 13, 2025 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today the launch of a secondary underwritten public offering of 9,000,000 shares of its common stock by certain of its stockholders. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 1,350,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Such selling stockholders will receive all of the proceeds from this offering. Loar is not selling any shares of common stock in this offering and will not receive any proceeds from this offering. Jefferies and Morgan Stanley are acting as lead book runners for the proposed offering. Blackstone is acting as co-manager. An automatic shelf registration statement (including a base prospectus) relating to this offering of common stock was filed by Loar with the Securities and Exchange Commission (the "SEC") on May 1, 2025 and became effec
Detego Global Announces Sponsorship of British Police Rugby Team for 2025 Centenary Tour of South Africa13.5.2025 12:30:00 CEST | Press release
HORSHAM, UNITED KINGDOM / ACCESS Newswire / May 13, 2025 / Following the resounding success of their sponsorship of the England Police Rugby Team's 2024 South African tour, Detego Global, the leading provider of cutting-edge digital forensics and investigative technology, is proud to announce its sponsorship of the British Police Rugby Team's 2025 centenary tour of South Africa, bringing together players from all four nations of England, Ireland, Scotland, and Wales. This new partnership strengthens a shared commitment to community engagement and global cooperation whilst marking an important occasion - the beginning of the British Police Rugby Team's centenary celebrations. Founded in 1925, the British Police Rugby Team has upheld a proud tradition of sporting excellence and service for a century. The 2025 tour of South Africa launches a year of commemorative events and fixtures, starting with two major matches, including one at the world-famous Hollywoodbets Kings Park Stadium in Dur
Loar Holdings Inc. Reports Q1 2025 Record Results and Upward Revision to 2025 Outlook13.5.2025 08:30:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 13, 2025 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our"), reported record results for the first quarter of 2025. First Quarter 2025 Net sales of $114.7 million, up 24.8% compared to the prior year's quarter. Net income of $15.3 million, up $13.1 million compared to the prior year's quarter. Diluted earnings per share of $0.16. Adjusted EBITDA of $43.1 million, up 30.6% compared to the prior year's quarter. Net income margin for the quarter improved to 13.4% compared to the prior year's quarter net income margin of 2.4%. Adjusted EBITDA Margin for the quarter improved to 37.6% compared to 36.0% for the prior year's quarter. Adjusted Earnings Per Share of $0.20. "We began 2025 with excellent momentum from strong demand across our end-markets," stated Dirkson Charles, Loar CEO and Executive Co-Chairman of the Board of Directors. "In the quarter, sales to our Original Equipment, Commercial Aftermarket and Defense marke
OMP's Unison Planning Achieves SAP(R) Certified Integration with RISE with SAP S/4HANA(R) Cloud13.5.2025 07:00:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / May 13, 2025 / OMP, a global leader in supply chain planning solutions, announced today that its Unison PlanningTM platform has achieved SAP® certification as integrated with RISE with SAP S/4HANA® Cloud. Continuing its long history of providing SAP-certified integration, this milestone confirms Unison Planning's full support for S/4HANA environments and its compatibility with RISE with SAP. The integration delivers seamless, near-real-time connectivity between SAP and Unison Planning's advanced supply chain capabilities, reinforcing OMP's role as a trusted partner for navigating complex planning environments. "Achieving this certification highlights our commitment to innovation and enterprise-grade reliability," says Tom Wouters, Chief Product Officer at OMP. "It confirms our ability to support global businesses in their digital transformation journeys, especially those migrating to S/4HANA with RISE with SAP." OMP was recently recognized as a Leader
BioNxt Reports Expanded Research, Development and Commercialization Capability with Centralized Munich Laboratory13.5.2025 03:05:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / May 13, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, is pleased to announce the integration of its research, development and commercialization activities to the Gen-Plus GmbH & Co. KG (Gen-Plus) Contract Research and Development Organization (CRDO) in Munich, Germany. The move provides BioNxt with enhanced R&D capabilities, collaboration opportunities, and accelerated innovation potential within a major European biotech hub. The Company seeks to leverage the advanced and innovative infrastructure of the Gen-Plus Laboratory and harness the facility's 1,000 square meters of state-of-the-art space designed for high-potency active pharmaceutical ingredients and GMP-compliant processes. The lab's specialized equipment, including advanced technologies for solid and semi-solid dosage forms and capabilities in drug printing, will empower BioNxt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom